Get the Stockscreener App
11.37
4.29%
-0.51
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Sellas Life Sciences Group Inc stock is traded at $11.37, with a volume of 3.00M.
It is down -4.29% in the last 24 hours and up +0.71% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$11.88
Open:
$11.5
24h Volume:
3.00M
Relative Volume:
0.66
Market Cap:
$2.30B
Revenue:
Net Income/Loss:
$-29.46M
P/E Ratio:
-49.80
EPS:
-0.2283
Net Cash Flow:
$-28.17M
1W Performance:
+0.98%
1M Performance:
+0.71%
6M Performance:
+131.57%
1Y Performance:
+421.56%
1-Day Range:
$11.15
$11.92
1-Week Range:
$11.26
$12.70
52-Week Range:
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
11.37 | 2.30B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - GlobeNewswire Inc.
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Life Sciences Companies Present Live at the September 17 Virtual Investor Forum - Yahoo Finance
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investigation launched into Sellas Life Sciences over delayed clinical trial results and stock drop - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - FinancialContent
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Science - The National Law Review
SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - PR Newswire
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against SELLAS Life Sciences Group, Inc. (SLS) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - natlawreview.com
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference - Yahoo Finance
SELLAS Life Sciences to Present Preclinical Data on SLS009 - GlobeNewswire
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here - Barchart.com
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED) - Yahoo Finance
Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears - finance.yahoo.com
BMF Capital Shorts SELLAS Life Sciences, Sees 76% DownsideSELLAS Life Sciences Gr (NASDAQ:SLS) - Benzinga
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Stocktwits
Is Uncertain Galinpepimut-S Data Timing Reshaping SELLAS Life Sciences Group’s (SLS) Strategic Story? - webull.com
When Will SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Breakeven? - 富途牛牛
SELLAS Life Sciences Group Stock (SLS) Opinions on REGAL Trial Catalyst - Quiver Quantitative
SELLAS Life Sciences Group, Inc. Tokenized Stock (Robinhood) to United States Dollar Price Today | Live SLS to USD Converter & Exchange Rate - CryptoRank
SELLAS Life Sciences Group, Inc. Tokenized Stock (Robinhood) Exchanges SLS Markets | Buy & Sell & Trade - CryptoRank
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges - Benzinga
Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline - Stocktwits
SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout - Stocktwits
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced - Stocktwits
SELLAS Shares Gain $416 Million With REGAL Trial Approaching Final Analysis - ts2.tech
Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative? - simplywall.st
Sellas Life Sciences Rides a Sector Wave as Its Own Leukemia Trial Hits the Home Stretch - Ad-hoc-news.de
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
SELLAS Shares Climb 15% as Market Values Company $2.98 Billion Over Cash Pre-AML Update - TechStock²
Sebring Design Build Featured in Newsweek on Why Affluent Williamson County Homeowners Are Remodeling Instead of Moving - Yahoo Finance
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
3 Healthcare Funds to Play Safe as Fed Readies for Rate Hike - Yahoo Finance
SELLAS Soars as Leukemia Trial Readout Sparks Speculation - TipRanks
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales? - Yahoo Finance
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission - Yahoo Finance
Citadel Sold More Than $4 Billion of Situational Awareness Bets - Yahoo Finance
Is the Options Market Predicting a Spike in Latham Group Stock? - Yahoo Finance
IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
Goldman Says Slowing Inflation Is Best Path to Lower US Yields - Yahoo Finance
Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses? - Yahoo Finance
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
12.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):